Revvity (NYSE:RVTY) Stock Moved Up to “Buy” by Cfra

Posted by Stanley Muller on Nov 5th, 2026

Cfra upgraded shares of Revvity (NYSE:RVTY – Free Report) from a hold rating to a buy rating in a research note released on Wednesday morning, Marketbeat reports.

Other equities analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 16th. Zacks Research upgraded shares of Revvity from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Barclays boosted their price target on shares of Revvity from $115.00 to $160.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 7th. Evercore restated an “outperform” rating on shares of Revvity in a research report on Wednesday, August 5th. Finally, Royal Bank Of Canada assumed coverage on Revvity in a research note on Tuesday, September 1st. They set a “sector perform” rating and a $135.00 price objective on the stock. Six investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $133.86.

Read Our Latest Stock Report on RVTY

Revvity Stock Performance

NYSE:RVTY opened at $159.68 on Wednesday. The company has a market capitalization of $17.82 billion, a price-to-earnings ratio of 29.46, a PEG ratio of 2.95 and a beta of 1.08. The business has a 50 day moving average of $146.58 and a 200 day moving average of $112.84. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.65 and a quick ratio of 1.50. Revvity has a 1-year low of $81.22 and a 1-year high of $171.74.

Revvity (NYSE:RVTY – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.30 by $0.08. The firm had revenue of $728.90 million for the quarter, compared to the consensus estimate of $694.73 million. Revvity had a net margin of 8.61% and a return on equity of 8.64%. The business’s revenue was up 4.3% compared to the same quarter last year. During the same period last year, the firm posted $1.18 earnings per share. On average, sell-side analysts predict that Revvity will post 5.41 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, February 12th. Stockholders of record on Friday, January 22nd will be issued a $0.07 dividend. The ex-dividend date is Friday, January 22nd. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. Revvity’s dividend payout ratio (DPR) is currently 13.33%.

Insider Buying and Selling at Revvity

In other Revvity news, insider Tajinder S. Vohra sold 7,330 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the sale, the insider owned 6,635 shares of the company’s stock, valued at $934,738.80. This represents a 52.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Maxwell Krakowiak sold 1,631 shares of the stock in a transaction on Monday, September 21st. The shares were sold at an average price of $144.53, for a total transaction of $235,728.43. Following the sale, the insider directly owned 14,781 shares of the company’s stock, valued at $2,136,297.93. The trade was a 9.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 9,045 shares of company stock worth $1,281,439. 0.85% of the stock is owned by insiders.

Hedge Funds Weigh In On Revvity

A number of institutional investors have recently added to or reduced their stakes in RVTY. Lido Advisors LLC increased its stake in shares of Revvity by 27.3% during the third quarter. Lido Advisors LLC now owns 4,510 shares of the company’s stock valued at $690,000 after purchasing an additional 968 shares in the last quarter. New York Life Investment Management LLC increased its holdings in Revvity by 4.6% in the 3rd quarter. New York Life Investment Management LLC now owns 31,457 shares of the company’s stock worth $4,809,000 after buying an additional 1,392 shares in the last quarter. AlphaCore Capital LLC raised its position in Revvity by 135.9% in the 3rd quarter. AlphaCore Capital LLC now owns 5,015 shares of the company’s stock worth $767,000 after buying an additional 2,889 shares during the last quarter. Fulcrum Asset Management LLP purchased a new position in Revvity in the 3rd quarter worth about $514,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in Revvity by 0.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,248,998 shares of the company’s stock valued at $335,236,000 after acquiring an additional 21,124 shares during the period. Institutional investors own 86.65% of the company’s stock.

Key Revvity News

Here are the key news stories impacting Revvity this week:

Positive Sentiment: Revvity beat third-quarter estimates, reporting adjusted EPS of $1.38 versus a $1.30 consensus and revenue of $728.9 million versus $694.7 million. Revenue increased 4.3% year over year, with Life Sciences strength and margin expansion cited, and the company raised its 2026 outlook. Q3 earnings and outlook
Positive Sentiment: CFRA upgraded the stock from Hold to Buy. TD Cowen also raised its price target to $185 and maintained a Buy rating, signaling further potential upside. TD Cowen price-target change
Neutral Sentiment: Other analysts raised targets but kept more cautious ratings: Barclays set $175 with Equal Weight, RBC set $172 with Sector Perform, and JPMorgan set $160 with Neutral. The range of views suggests analysts see improvement, but not uniform conviction. JPMorgan price-target change
Negative Sentiment: Valuation may temper enthusiasm: coverage questioned whether the stock is now too expensive, while JPMorgan’s new target is close to the referenced share price. This could contribute to a pullback even after the earnings beat. Valuation and dividend coverage

Revvity Company Profile

(Get Free Report)

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.